Leerink Partners analyst David Risinger has maintained their bullish stance on XOMA stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Risinger has given his Buy rating due to a combination of factors that suggest a positive outlook for Xoma’s stock. Risinger likely sees potential in Xoma’s strategic positioning within the biopharmaceutical industry, which could be bolstered by recent developments in drug pricing negotiations led by key figures such as Mehmet Oz. The expectation of increased drug prices in international markets, coupled with the potential for reduced U.S. drug prices, might create a favorable environment for companies like Xoma.
Additionally, Risinger might be considering the broader implications of the ‘most favored nation’ pricing model, which could impact the entire sector. Xoma’s ability to navigate these complex pricing dynamics and trade negotiations could position it well for future growth. Risinger’s analysis likely reflects confidence in Xoma’s management and its strategic initiatives to capitalize on these market conditions, thus justifying the Buy rating.
According to TipRanks, Risinger is a 5-star analyst with an average return of 7.9% and a 52.98% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Johnson & Johnson, and Sanofi.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $104.00 price target.